March 14, 2023
Decibel Therapeutics
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
March 13, 2023
Pliant Therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
March 09, 2023
Fulcrum Therapeutics
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 09, 2023
Abata Therapeutics
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
March 08, 2023
Pliant Therapeutics
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors